Vijay Kumar
Stock Analyst at Evercore ISI Group
(3.30)
# 1,016
Out of 5,147 analysts
289
Total ratings
50.28%
Success rate
1.39%
Average return
Main Sectors:
Stocks Rated by Vijay Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CAI Caris Life Sciences | Maintains: Outperform | $38 → $34 | $20.14 | +68.82% | 3 | Feb 27, 2026 | |
| PEN Penumbra | Maintains: Outperform | $340 → $360 | $344.39 | +4.53% | 3 | Feb 26, 2026 | |
| USB U.S. Bancorp | Maintains: In-Line | $60 → $65 | $54.66 | +18.92% | 8 | Feb 5, 2026 | |
| GEHC GE HealthCare Technologies | Maintains: Outperform | $95 → $98 | $84.27 | +16.29% | 6 | Feb 5, 2026 | |
| BSX Boston Scientific | Maintains: Outperform | $112 → $96 | $76.85 | +24.92% | 8 | Feb 5, 2026 | |
| AZTA Azenta | Maintains: Outperform | $50 → $45 | $26.98 | +66.79% | 10 | Feb 5, 2026 | |
| TWST Twist Bioscience | Maintains: Outperform | $42 → $52 | $46.92 | +10.83% | 7 | Feb 3, 2026 | |
| RVTY Revvity | Maintains: Outperform | $112 → $118 | $98.31 | +20.03% | 4 | Feb 3, 2026 | |
| ISRG Intuitive Surgical | Maintains: In-Line | $580 → $550 | $503.51 | +9.23% | 15 | Jan 23, 2026 | |
| ABT Abbott Laboratories | Maintains: Outperform | $144 → $138 | $116.35 | +18.61% | 18 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $168 → $223 | $233.41 | -4.46% | 9 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $79 → $78 | $75.36 | +3.50% | 17 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $105 | $103.38 | +1.57% | 8 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $18 | $18.30 | -1.64% | 12 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $14 → $12 | $9.05 | +32.60% | 13 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $94 → $120 | $98.44 | +21.90% | 15 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $194 → $210 | $133.75 | +57.01% | 3 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $155 → $160 | $121.38 | +31.82% | 8 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $410 → $405 | $387.46 | +4.53% | 13 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $132 → $142 | $134.46 | +5.61% | 9 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $88 → $92 | $86.47 | +6.40% | 15 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $525 → $590 | $521.11 | +13.22% | 13 | Oct 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,275 → $1,400 | $1,366.69 | +2.44% | 12 | Oct 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $226 → $245 | $210.64 | +16.31% | 4 | Oct 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $31 | $20.37 | +52.18% | 8 | Oct 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $103 → $106 | $97.66 | +8.54% | 5 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $46 | $25.47 | +80.60% | 4 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $3 | $3.15 | -4.76% | 6 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $18 → $30 | $13.67 | +119.46% | 11 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $335 → $355 | $319.38 | +11.15% | 8 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $160 | $96.57 | +65.68% | 7 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $286 → $290 | $176.48 | +64.32% | 6 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $1.07 | +554.21% | 1 | May 31, 2022 |
Caris Life Sciences
Feb 27, 2026
Maintains: Outperform
Price Target: $38 → $34
Current: $20.14
Upside: +68.82%
Penumbra
Feb 26, 2026
Maintains: Outperform
Price Target: $340 → $360
Current: $344.39
Upside: +4.53%
U.S. Bancorp
Feb 5, 2026
Maintains: In-Line
Price Target: $60 → $65
Current: $54.66
Upside: +18.92%
GE HealthCare Technologies
Feb 5, 2026
Maintains: Outperform
Price Target: $95 → $98
Current: $84.27
Upside: +16.29%
Boston Scientific
Feb 5, 2026
Maintains: Outperform
Price Target: $112 → $96
Current: $76.85
Upside: +24.92%
Azenta
Feb 5, 2026
Maintains: Outperform
Price Target: $50 → $45
Current: $26.98
Upside: +66.79%
Twist Bioscience
Feb 3, 2026
Maintains: Outperform
Price Target: $42 → $52
Current: $46.92
Upside: +10.83%
Revvity
Feb 3, 2026
Maintains: Outperform
Price Target: $112 → $118
Current: $98.31
Upside: +20.03%
Intuitive Surgical
Jan 23, 2026
Maintains: In-Line
Price Target: $580 → $550
Current: $503.51
Upside: +9.23%
Abbott Laboratories
Jan 23, 2026
Maintains: Outperform
Price Target: $144 → $138
Current: $116.35
Upside: +18.61%
Jan 13, 2026
Maintains: Outperform
Price Target: $168 → $223
Current: $233.41
Upside: -4.46%
Jan 5, 2026
Downgrades: In-Line
Price Target: $79 → $78
Current: $75.36
Upside: +3.50%
Jan 5, 2026
Downgrades: In-Line
Price Target: $105
Current: $103.38
Upside: +1.57%
Jan 5, 2026
Downgrades: In-Line
Price Target: $18
Current: $18.30
Upside: -1.64%
Jan 5, 2026
Downgrades: In-Line
Price Target: $14 → $12
Current: $9.05
Upside: +32.60%
Jan 5, 2026
Upgrades: Outperform
Price Target: $94 → $120
Current: $98.44
Upside: +21.90%
Jan 5, 2026
Upgrades: Outperform
Price Target: $194 → $210
Current: $133.75
Upside: +57.01%
Jan 5, 2026
Upgrades: Outperform
Price Target: $155 → $160
Current: $121.38
Upside: +31.82%
Oct 31, 2025
Maintains: Outperform
Price Target: $410 → $405
Current: $387.46
Upside: +4.53%
Oct 31, 2025
Maintains: Outperform
Price Target: $132 → $142
Current: $134.46
Upside: +5.61%
Oct 31, 2025
Maintains: Outperform
Price Target: $88 → $92
Current: $86.47
Upside: +6.40%
Oct 7, 2025
Maintains: Outperform
Price Target: $525 → $590
Current: $521.11
Upside: +13.22%
Oct 7, 2025
Maintains: Outperform
Price Target: $1,275 → $1,400
Current: $1,366.69
Upside: +2.44%
Oct 7, 2025
Maintains: Outperform
Price Target: $226 → $245
Current: $210.64
Upside: +16.31%
Oct 7, 2025
Maintains: Outperform
Price Target: $33 → $31
Current: $20.37
Upside: +52.18%
Jul 8, 2025
Maintains: Outperform
Price Target: $103 → $106
Current: $97.66
Upside: +8.54%
Jul 8, 2025
Maintains: Outperform
Price Target: $48 → $46
Current: $25.47
Upside: +80.60%
May 19, 2025
Maintains: In-Line
Price Target: $3
Current: $3.15
Upside: -4.76%
Dec 2, 2024
Upgrades: Outperform
Price Target: $18 → $30
Current: $13.67
Upside: +119.46%
Oct 1, 2024
Maintains: In-Line
Price Target: $335 → $355
Current: $319.38
Upside: +11.15%
Oct 1, 2024
Maintains: Outperform
Price Target: $120 → $160
Current: $96.57
Upside: +65.68%
Oct 1, 2024
Maintains: Outperform
Price Target: $286 → $290
Current: $176.48
Upside: +64.32%
May 31, 2022
Initiates: Outperform
Price Target: $7
Current: $1.07
Upside: +554.21%